药物多晶型的研究进展

摘要

多晶型研究是制药领域的一个研究热点，而多晶型体系的分子组装规律及其控制手段是最为关键的研究内容。介绍了多晶型的分子组装规律，即成核理论（包括经典成核理论以及新兴的二步成核理论），以及多晶型的调控方法，并重点介绍目前新型的调控手段（如离子液体、模板剂以及微通道技术等）。此外，结合药物晶型转化的实际案例，说明晶型转化技术在药物产品质量调控中的重要作用。

	Service

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	Email Alert
	RSS
	作者相关文章
	赵绍磊
	王灵宇
	吴送姑

关键词：药物多晶型；成核理论；晶型控制；晶型转化

Abstract：

The study on pharmaceutical polymorphs is a hot topic in the field of drug. Meanwhile, the molecular assembly rules and the controlling methods of pharmaceutical polymorphs are the key contents in the research of polymorphs. In this paper, the nucleation theories, including the classical nucleation theory and two-step nucleation theory, as well as the methods about how to control pharmaceutical polymorph are introduced. In particular, some new strategies for polymorph regulation are highlighted, such as ionic liquid, template agent and microchannel technology. In addition, two practical examples are used to illustrate the important role of phase transformation in improving the quality of pharmaceutical products.

Keywords： pharmaceutical polymorph； nucleation theory； polymorph regulation； phase transformation

Received 2018-03-30;

Fund:

国家自然科学基金创新研究群体项目（21621004）和国家科技重大专项（2017ZX09101001）。

Corresponding Authors: 吴送姑,E-mail:wusonggu@tju.edu.cn。 Email: wusonggu@tju.edu.cn

About author: 赵绍磊(1994-),男,硕士研究生,现从事工业结晶方面的研究。

引用本文:

赵绍磊, 王灵宇, 吴送姑.药物多晶型的研究进展[J]. 化学工业与工程, 2018,35(3): 12-21

Zhao Shaolei, Wang Lingyu, Wu Songgu.Progress in the Research of Pharmaceutical Polymorph[J]. Chemcial Industry and Engineering, 2018,35(3): 12-21

[1] Cruz-Cabeza A J, Reutzel-Edens S M, Bernstein J. Facts and fictions about polymorphism[J]. Chemical Society Reviews,2015, 44(23):8619-8635
[2] Hilfiker, R. Polymorphism in the pharmaceutical industry[M]. Weinheim, Germany:Wiley-VCH, 2006
[3] Karthika S, Radhakrishnan T K, Kalaichelvi P. A review of classical and nonclassical nucleation theories[J]. Crystal Growth & Design,2016, 16(11):6663-6681
[4] Erdemir D, Lee A Y, Myerson A S. Nucleation of crystals from solution:Classical and two-step models[J]. Accounts of Chemical Research,2009, 42(5):621-629
[5] Davey R J, Schroeder S L M, Ter Horst J H, et al. Nucleation of organic crystals-A molecular perspective[J]. Angewandte Chemie International Edition, 2013, 52(8):2166-2179
[6] Cavallo D, Alfonso G C. Concomitant crystallization and cross-nucleation in polymorphic polymers[M]. Germany:Springer International Publishing, 2017
[7] Desgranges C, Delhommelle J. Molecular mechanism for the cross-nucleation between polymorphs[J]. Journal of the American Chemical Society,2006, 128(32):10368-10369
[8] Yu L. Nucleation of one polymorph by another[J]. Journal of the American Chemical Society,2003, 125(21):6380-6381
[9] Bernstein J, Davey R J, Henck J O. Concomitant polymorphs[J]. Angewandte Chemie International Edition,1999, 38(23):3440-3461
[10] 杜威. 普拉格雷盐酸盐伴随多晶型和托芬那酸构象多晶型行为研究[D]. 天津:天津大学, 2015 Du Wei. A study on concomitant polymorphism of prasugrel hydrochloride and conformational polymorphism of tolfenamic acid[D]. Tianjin:Tianjin University, 2015(in Chinese)
[11] Du W, Yin Q, Bao Y, et al. Concomitant polymorphism of prasugrel hydrochloride in reactive crystallization[J]. Industrial & Engineering Chemistry Research,2013, 52(46):16182-16189
[12] Jiang S, Horst J H T, Jansens P J. Concomitant polymorphism of o-aminobenzoic acid in antisolvent crystallization[J]. Crystal Growth & Design,2008, 8(1):37-43
[13] Kitamura M. Strategy for control of crystallization of polymorphs[J]. Cryst Eng Comm,2009, 11(6):949-964
[14] Llinàs A, Goodman J M. Polymorph control:Past, present and future[J]. Drug Discovery Today,2008, 13(5):198-210
[15] Newman A. Specialized solid form screening techniques[J]. Organic Process Research & Development, 2013, 17(3):457-471
[16] Gu C, Li H, Gandhi R B, et al. Grouping solvents by statistical analysis of solvent property parameters:Implication to polymorph screening[J]. International Journal of Pharmaceutics,2004, 283(1):117-125
[17] Zeglinski J, Kuhs M, Khamar D, et al. Crystal nucleation of tolbutamide in solution:Relationship to solvent, solute conformation, and solution structure[J]. Chemistry-A European Journal,2018, 24(19):4916-4926
[18] Beckmann W. Seeding the desired polymorph:Background, possibilities, limitations, and case studies[J]. Org process Res Dev,2000, 4(5):372-383
[19] Mo Y, Dang L, Wei H. L-Glutamic acid polymorph control using amino acid additives[J]. Industrial & Engineering Chemistry Research,2011, 50(18):10385-10392
[20] Simone E, Steele G, Nagy Z K. Tailoring crystal shape and polymorphism using combinations of solvents and a structurally related additive[J]. Cryst Eng Comm,2015, 17(48):9370-9379
[21] Weissbuch I, Leisorowitz L, Lahav M."Tailor-Made"and charge-transfer auxiliaries for the control of the crystal polymorphism of glycine[J]. Advanced Materials, 1994, 6(12):952-956
[22] Dowling R, Davey R J, Curtis R A, et al. Acceleration of crystal growth rates:An unexpected effect of tailor-made additives[J]. Chemical Communications,2010, 46(32):5924-5926
[23] Gu C, Chatterjee K, Young V, et al. Stabilization of a metastable polymorph of sulfamerazine by structurally related additives[J]. Journal of Crystal Growth, 2002, 235(1):471-481
[24] Ventura S P M, E Silva F A, Quental M V, et al. Ionic-Liquid-Mediated extraction and separation processes for bioactive compounds:Past, present, and future trends[J]. Chemical Reviews,2017, 117(10):6984-7052
[25] An J, Jin F, Kim H S, et al. Application of ionic liquid to polymorphic transformation of anti-viral/HIV drug adefovir dipivoxil[J]. Archives of Pharmacal Research, 2016, 39(5):646-659
[26] Martins I C B, Gomes J R B, Duarte M T, et al. Understanding polymorphic control of pharmaceuticals using imidazolium-based ionic liquid mixtures as crystallization directing agents[J]. Crystal Growth & Design, 2017, 17(2):428-432
[27] An J H, Kim J M, Chang S M, et al. Application of ionic liquid to polymorphic design of pharmaceutical ingredients[J]. Crystal Growth & Design, 2010, 10(7):3044-3050
[28] An J H, Kim W S. Antisolvent crystallization using ionic liquids as solvent and antisolvent for polymorphic design of active pharmaceutical ingredient[J]. Crystal Growth & Design, 2013, 13(1):31-39
[29] An J H, Jin F, Kim H S, et al. Investigation of the polymorphic transformation of the active pharmaceutical ingredient clopidogrel bisulphate using the ionic liquid AEImBF4[J]. Crystal Growth & Design,2016, 16(4)
[30] Zeng Q, Mukherjee A, Müller P, et al. Exploring the role of ionic liquids to tune the polymorphic outcome of organic compounds[J]. Chemical Science,2017, 9(6)
[31] Lang M, Grzesiak A L, Matzger A J. The use of polymer heteronuclei for crystalline polymorph selection[J]. Journal of the American Chemical Society, 2002, 124(50):14834-14835
[32] Price C P, Grzesiak A L, Matzger A J. Crystalline polymorph selection and discovery with polymer heteronuclei[J]. Journal of the American Chemical Society, 2005, 127(15):5512-5517
[33] Foroughi L M, Kang Y N, Matzger A J. Polymer-Induced heteronucleation for protein single crystal growth:Structural elucidation of bovine liver catalase and concanavalin A forms[J]. Crystal Growth & Design, 2011, 11(4):1294-1298
[34] López-Mejías V, Knight J L, Brooks C L, et al. On the mechanism of crystalline polymorph selection by polymer heteronuclei[J]. Langmuir, 2011, 27(12):7575-7579
[35] Pfund L Y, Price C P, Frick J J, et al. Controlling pharmaceutical crystallization with designed polymeric heteronuclei[J]. Journal of the American Chemical Society,2015, 137(2):871-875
[36] Frank D S, Matzger A J. Influence of chemical functionality on the rate of polymer-induced heteronucleation[J]. Crystal Growth & Design, 2017, 17(8):4056-4059
[37] Quiñones R, Brown R T, Searls N, et al. Study of polymorphism using patterned self-assembled monolayers approach on metal substrates[J]. Applied Surface Science,2018, 427:97-105
[38] Harano K, Homma T, Niimi Y, et al. Heterogeneous nucleation of organic crystals mediated by single-molecule templates[J]. Nature Materials,2012, 11(10):877-881
[39] Hiremath R, Basile J A, And S W V, et al. Controlling molecular crystal polymorphism with self-assembled monolayer templates[J]. Journal of the American Chemical Society,2005, 127(51):18321-18327
[40] Cui Y, Stojakovic J, Kijima H, et al. Mechanism of contact-induced heterogeneous nucleation[J]. Crystal Growth & Design, 2016, 16(10):6131-6138
[41] Zhang J, Liu A, Han Y, et al. Effects of self-assembled monolayers on selective crystallization of tolbutamide[J]. Crystal Growth & Design,2011, 11(11):5498-5506
[42] Yang X, Sarma B, Myerson A S. Polymorph control of micro/nano-sized mefenamic acid crystals on patterned self-assembled monolayer islands[J]. Crystal Growth & Design,2012, 12(12):5521-5528
[43] Shi H, Xiao Y, Ferguson S, et al. Progress of crystallization in microfluidic devices[J]. Lab on a Chip, 2017, 17(13):2167-2185
[44] 蒋楠. 液滴-微流体环境下L-谷氨酸多晶型现象研究[D]. 天津:天津大学, 2016 Jiang Nan. The polymorph studies of L-glutanmic acid under droplet-microfluidic system[D]. Tianjin:Tianjin University, 2016(in Chinese)
[45] And O G, Peter G V. Are nucleation kinetics of protein crystals similar to those of liquid droplets?[J]. J Am Chem Soc, 2000, 122(1):156-163
[46] Yamaguchi H, Maeki M, Yamashita K, et al. Controlling one protein crystal growth by droplet-based microfluidic system[J]. Journal of Biochemistry, 2013, 153(4):339-346
[47] Maeki M, Yoshizuka S, Yamaguchi H, et al. X-Ray diffraction of protein crystal grown in a nano-liter scale droplet in a microchannel and evaluation of its applicability[J]. Analytical Sciences, 2012, 28(28):65
[48] Laval P, Giroux C, Leng J, et al. Microfluidic screening of potassium nitrate polymorphism[J]. Journal of Crystal Growth, 2008, 310(12):3121-3124
[49] Ding L, Zong S, Dang L, et al. Effects of inorganic additives on polymorphs of glycine in microdroplets[J]. Cryst Eng Comm,2017, 20(2)
[50] Jiang N, Wang Z, Dang L, et al. Effect of supersaturation on L-glutamic acid polymorphs under droplet-based microchannels[J]. Journal of Crystal Growth,2016, 446:68-73
[51] Teshima Y, Maeki M, Yamashita K, et al. A method for generating a metastable crystal in a microdroplet[J]. Crystengcomm,2013, 15(46):9874-9877
[52] Chemburkar S R, Bauer J, Deming K, et al. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development[J]. Organic Process Research & Development,2000, 4(5):413-417
[53] Du W, Yin Q, Hao H. Solution-Mediated polymorphic transformation of prasugrel hydrochloride from form Ⅱ to Form I[J]. Industrial & Engineering Chemistry Research, 2014, 53(14):5652-5659
[54] Jiang S, Jansens P J, ter Horst J H. Mechanism and kinetics of the polymorphic transformation of o-aminobenzoic acid[J]. Crystal Growth & Design, 2010, 10(5):2123-2128
[55] Wu C D, Lin W. Highly Porous, Homochiral metal-organic frameworks:Solvent-exchange-induced single-crystal to single-crystal transformations[J]. Angewandte Chemie International Edition,2005, 44(13):1958-1961
[56] 龚俊波,王琦,董伟兵,等. 药物晶型转化与控制的研究进展[J]. 化工学报, 2013, (2):385-392 Gong Junbo, Wang Qi, Dong Weibing, et al. Progress on transformation and manipulation of drug polymorphism[J]. Journal of Chemical Industry and Engineering, 2013, (2):385-392(in Chinese)
[57] Mangin D, Puel F, Veesler S. Polymorphism in processes of crystallization in solution:A practical review[J]. Organic Process Research & Development, 2009, 13(6):1241-1253
[58] Wu S, Shen H, Li K, et al. Agglomeration mechanism of azithromycin dihydrate in acetone-water mixtures and optimization of the powder properties[J]. Industrial & Engineering Chemistry Research, 2016, 55(17):4905-4910
[59] Wu S, Du Shichao, Chen M, et al. Crystal structures and phase behavior of sulfadiazine and a method for the preparation of aggregates with good performance[J]. Chemical Engineering & Technology, 2018, 41(3):532-540
[60] Wu S, Chen M, Li K, et al. Solvent penetration mediated phase transformation for the preparation of aggregated particles with well-defined shape[J]. Cryst Eng Comm. 2016, 18(48):9223-9226